X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PCRX-201 (enekinragene inzadenovec), the high-capacity adenoviral gene therapy vector codes for IL-1Ra expression, a cytokine inhibitor that plays a central role in blocking inflammation and catabolic processes associated with pain and disease progression in osteoarthritis.
Lead Product(s): Enekinragene Inzadenovec
Therapeutic Area: Musculoskeletal Product Name: PCRX-201
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2024
Details:
Through the agreement, Premier will have access of EXPAREL (bupivacaine), a single-dose local and regional analgesic that provides prolonged postsurgical pain control while reducing reliance on opioids.
Lead Product(s): Bupivacaine
Therapeutic Area: Neurology Product Name: Exparel
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Premier
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 07, 2024
Details:
EXPAREL® (bupivacaine liposome injectable suspension) expand label to include administration in adults as an adductor canal block and a sciatic nerve block in the popliteal fossa.
Lead Product(s): Bupivacaine
Therapeutic Area: Neurology Product Name: Exparel
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2023
Details:
Second Phase 3 study of EXPAREL (bupivacaine) achieves primary and key secondary endpoints; safely demonstrating statistically significant reductions in postsurgical pain and opioid consumption through 96 hours.
Lead Product(s): Bupivacaine
Therapeutic Area: Neurology Product Name: Exparel
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2022
Details:
EXPAREL achieved the study’s primary endpoint demonstrating a statistically significant reduction in cumulative pain scores from 0 to 96 hours compared with bupivacaine HCl (p<0.01).
Lead Product(s): Bupivacaine
Therapeutic Area: Neurology Product Name: Exparel
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
GNSC-001 is an adeno-associated vector (AAV) carrying a coding sequence for interleukin-1 receptor antagonist (IL-1Ra), a potent inhibitor of interleukin-1 (IL-1) signaling.
Lead Product(s): sc-rAAV2.5IL-1Ra
Therapeutic Area: Musculoskeletal Product Name: GNSC-001
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Recipient: Genascence
Deal Size: $10.5 million Upfront Cash: Undisclosed
Deal Type: Series A Financing May 10, 2022
Details:
This acquisition is a major milestone to build a robust offering of novel, non-opioid treatments to improve patient care along the neural pain pathway while simultaneously providing a complementary commercial asset in ZILRETTA for the treatment of OA knee pain.
Lead Product(s): Triamcinolone Acetonide
Therapeutic Area: Neurology Product Name: Zilretta
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Flexion Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 11, 2021
Details:
Under the terms of the agreement, Eurofarma obtains the exclusive right to market and distribute EXPAREL in 19 countries in Latin America, including Argentina, Brazil, Colombia, and Mexico.
Lead Product(s): Bupivacaine
Therapeutic Area: Neurology Product Name: Exparel
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eurofarma Laboratorios S.A
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 22, 2021
Details:
Company to expand FX201 low dose and mid dose cohorts to include up to 20 additional patients in each treatment group. Clinical data from the first two cohorts indicate that FX201 appears to be generally safe and well-tolerated at the low and mid doses.
Lead Product(s): Humantakinogene hadenovec
Therapeutic Area: Musculoskeletal Product Name: FX201
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 18, 2021
Details:
Previously presented preclinical findings show FX301 provided greater sustained, post-operative analgesic effect with no significant impairment in motor function compared to liposomal bupivacaine and placebo.
Lead Product(s): Funapide
Therapeutic Area: Neurology Product Name: FX301
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
